The news: Digital health company Noom is offering access to compounded semaglutide as part of a new program for members. The weight loss startup is the latest online healthcare player to take advantage of brand-name GLP-1s in shortage by providing cheaper alternatives.
- The program, called GLP-1Rx, will start at $149/month and include access to compounded semaglutide if deemed clinically appropriate by a physician, regardless of insurance coverage.
- For context, Noom has also been offering branded GLP-1 drugs such as Ozempic and Wegovy since last year.